Search

Your search keyword '"Lafeber, Melvin"' showing total 145 results
Start Over Author "Lafeber, Melvin"
145 results on '"Lafeber, Melvin"'

2. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M., Tan, Ngoc H., Rietdijk, Wim J. R., Geers, Daryl, Sablerolles, Roos S. G., Bogers, Susanne, van Dijk, Laura L. A., Gommers, Lennert, van Leeuwen, Leanne P. M., Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Dalm, Virgil A. S. H., Lafeber, Melvin, Kootstra, Neeltje A., Huckriede, Anke L. W., Haagmans, Bart L., van Baarle, Debbie, Koopmans, Marion P. G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2024
Full Text
View/download PDF

3. Association between Clinical Frailty Scale and mortality 24 months after hospitalisation in adult patients with COVID-19

Author

Aleman, Jacomien, Tournoy, Jos, Van der Linden, Lorenz, Gambera, Marco, Martignoni, Isabella, Van Etten, Ronald, van Onzenoort, Hein, Kappers, Mariette, van Wijngaarden, Peter, Verstijnen, Jose, Theeuwes, Vera, Kemper, Marleen, Slob, Elise, Sombogaard, Ferdi, Abdullah-Koolmees, Heshu, van den Berg, Roland, de Wit, Hugo, Dilek, Betul, Hogenhuis, Freija, Buyukayten, Vahid, te Brake, Britt, Nieuwenhuijzen, Margriet, Scheeren, Maria, de Wit, Madelief, Bulsink, Arjan, van Haelst, Ingrid, ter Horst, Peter, Moorlag, Rosalie, Vos, Anja, Otten-Helmers, Annemiek, van Kan, Erik, Voskamp, Marije, Ebbens, Marieke, Ezinga, Marieke, van Nieuwkoop, Cees, Visser, Loes, Ghazarian, Caroline, Hilarius, Doranne, Hermanides, Gonneke, Bresser, Carlinda, Derijks-Engwegen, Judith, Boemaars, Ebbie, Getrouw, Zahira, Maat, Barbara, Wierenga, Peter, Bosch, Tessa, Krens, Lisanne, Liang, Kajie, Saleh, Langeza, van Heuckelum, Milou, Hendriksen, Linda, van der Linden, Paul, Guda, Kaylen, Crommentuijn, Kristel, Cornelissen-Wesseling, Ilse, Diepstraten, Jeroen, Ellerbroek, Jacobien, Coenradie, Saskia, Deben, Debbie, Hurkens, Kim, Wong, Dennis, Vromen, Marion, de Bock, Marjolein, Savelkoul, Suzan, Wolters, Saskia, Andrews, Louise, Jong, Eefje, Kranenburg, Rosanne, Soares, Joana, Falcao, Fatima, Solano, Mariana, Viegas, Erica, Falcao, Margarida, Farinha, Helena, Mendes, Dina, Rijo, Joao, Miarons, Marta, Gorgas, Maria Queralt, Yubero, Cristina García, Portillo Horcajada, Laura, Keijzers, Kim, Lim, Silke, Ashfield, Linden, Bell, Helen, Fitzhugh, Naomi, Fleming, Glenda, Goodfellow, Nicola, Hanley, Joanne, Scott, Michael, Mooijaart, Simon P., Gussekloo, Jacobijn, Elders, Petra, Peeters, Geeske, Minnema, Julia, Lafeber, Melvin, Sablerolles, Roos S.G., van Kempen, Janneke A.L., Tap, Lisanne, Polinder-Bos, Harmke A., van de Loo, Bob P.A., van der Kuy, Hugo, and Faes, Miriam C.

Published
2024
Full Text
View/download PDF

4. Patient-Level Pooled Analysis of Endovascular Ultrasound Renal Denervation or a Sham Procedure 6 Months After Medication Escalation: The RADIANCE Clinical Trial Program

Author

Azizi, Michel, Sharp, Andrew S.P., Fisher, Naomi D.L., Weber, Michael A., Lobo, Melvin D., Daemen, Joost, Lurz, Philipp, Mahfoud, Felix, Schmieder, Roland E., Basile, Jan, Bloch, Michael J., Saxena, Manish, Wang, Yale, Sanghvi, Kintur, Jenkins, J. Stephen, Devireddy, Chandan, Rader, Florian, Gosse, Philippe, Claude, Lisa, Augustin, Dimitri A., McClure, Candace K., Kirtane, Ajay J., Wang, Yale, Skeik, Nedaa, Bae, Richard, McMeans, Amy, Goldman, JoAnne, Peterson, Rose, Stephen Jenkins, James, Tutor, Isabelle, Harrison, Michael, Penning, Angel, Devireddy, Chandan, Lea, Janice, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Tran, Anne, Bhatia, Kirin, Fisher, Naomi D.L., Sobieszczyk, Piotr, Halliday, Ian, Munson, Tay, Lindsey, Jason, Laster, Steven, Bunte, Mathew, Hart, Anthony, King, Dana, Hall, Jamie, Sanghvi, Kintur, Krathen, Courtney, Lewis, Luot, Willitts, Ashley, Todoran, Thomas, Basile, Jan, Awkar, Anthony, Palmer, Casey, Tecklenburg, Anna, Schindler, John, Pacella, John, Muldoon, Matthew, Albright, MaryJo, Nicholson, Tracy, Flack, John, Chami, Youseff, Hafiz, Abdul Moiz, Starkey, Emily, Adams, Kristal, Bernardo, Nelson, Veis, Judith, Hashim, Hayder, Singh, Suman, Whitman, Donna, Stouffer, Rick, Hinderliter, Alan, Allen, Meghan, Scholl, Tatum, Fong, Pete, Gainer, James, Crook, Sherron, Hatchcock, Ellen, Cohen, Debbie, Giri, Jay, Kobayashi, Taisei, Neubauer, Robin, Naidu, Suveeksha, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Khuddus, Matheen, Zentko, Suzanne, Touchton, Abby, Roberson, Marti, Bloch, Michael J., Akinapelli, Abhilash, English, Lisa, Neumann, Bridget, Mendelsohn, Farrel, Brantley, Hutton, Cawthon, Thomas, DeRamus, Susan, Wade, Wesley, Fishman, Robert, Tuohy, Edward, LeBlanc, Jessica, McCurry, Tina, Krishnaswamy, Amar, Laffin, Luke, Bajzer, Christopher, Boros, Marilyn, Branche, Monica, Abraham, Josephine, Abraham, Anu, Stijleman, Inge, Hsi, David, Martin, Scott, Portnay, Edward, Fiebach, Maryann, Garavito, Carolina, Adams, Todd, Teklinski, Andrew, Leech, Adam, Drilling, Patrick, Tulik, Lynda, Benzuly, Keith, Paparello, James, Fintel, Dan, Ramirez, Haydee, Kats, Lauren, Huang, Paul, Biswas, Santanu, Risher, Serena, Pratt, Kristina, Ibebuogu, Uzoma, Johnson, Karen, Cushman, William, Jones, Lisa, Jackson, Leigh, Landers, David, Pasala, Tilak, Salazer, Thomas, Canino, Peter, Arakelian, Patricia, Yang, Yi-Ming, Khaliq, Asma, Weinberg, Mitchell, Abetu, Yihenew, Gulliver, Alana, Reilly, J.P., Garasic, Joseph, Chugh, Atul, Bertolet, Barry, Go, Brian, Gallapudi, Raghava, Cohn, Joel, Rogers, Kevin, Saxena, Manish, Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Oliver, Topham, Christine, Sharp, Andrew, Anderson, Richard, Thompson, Elizabeth, Spiro, Nikki, Hodges, Elizabeth, Holder, Jaqueline, Ellam, Timothy, Bagnall, Alan, Jackson, Ralph, Bridgett, Victoria, Wilson, Peter, Das, Neelanjan, Doulton, Timothy, Loader, David, Hector, Gemma, Levy, Terry, Bent, Clare, Kodoth, Vivek, Horler, Stephanie, Nix, Sara, Robinson, Nicholas, Al-Janabi, Firas, Sayer, Jeremy, Ganesh Iyer, Sudha, Redman, Emily, Ramirez, Jonaifah, Padmanabhan, Sandosh, Sharif, Faisal, Alhmoudi, Aishah, Lunardi, Mattia, Coen, Eileen, Glynn, Nicola, Mahfoud, Felix, Lauder, Lucas, Kulenthiran, Saarraaken, Koch, Christina, Wachter, Angelika, Schmieder, Roland, Schmid, Axel, Kannenkeril, Dennis, Heinritz, Ulrike, Endres-Frohlich, Kerstin, Lurz, Philipp, Rommel, Karl, Fengler, Petzold, Martin, Büttner, Margit, Weil, Joachim, Agdirlioglu, Tolga, Köllner, Tanja, Stephan, Jeannine, Dagkonakis, Nikolaos, Hamann, Frank, Ettl, Ute, Petzsche, Ulrike, Reimer, Peter, Hausberg, Martin, Hinrichs, Ralf, Di Ponio-Voit, Isabella, Lutz, Matthias, Gosse, Philippe, Cremer, Antoine, Papadopoulos, Panteleimon, Gaudissard, Julie, Maire, Florent, Azizi, Michel, Sapoval, Marc, Livrozet, Marine, Regrag, Asma, Paquet, Valerie, Delsart, Pascal, Hennicaux, Justin, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Lafeber, Melvin, Zeijen, Victor, Ruiter, Amo, Huijskens, Elisabeth, van Ramshorst, Jan, Xaplanteris, Panagiotis, Briki, Rachid, de Hemptinne, Quentin, Pascal, Severine, Renard, Katty, Ferdinande, Bert, Iglesias, Juan F., Ehert, Georg, Gallego, Laetitia, Dobretz, Kevin, Bottone, Sylviane, Sanghvi, Kintur, Costello, Josh, Krathan, Courtney, Lewis, Luot, McElvarr, Andrew, Reilly, John, Jenkins, Stephen, Cash, Michael, Williams, Shannon, Jarvis, Maria, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Crook, Sherron, Maddel, Sarita, Hsi, David, Martin, Scott, Portnay, Edward, Ducey, Maryanne, Rose, Suzanne, DelMastro, Elizabeth, Bangalore, Sripal, Williams, Stephen, Cabos, Stanley, Rodriguez Alvarez, Carolina, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Paladugu, Vijay, Tecklenburg, Anna, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Fiebach, Amanda, Merlin, Claudia, Rader, Florian, Dohad, Suhail, Kim, Hyun-Min, Rashid, Mohammad, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Lavasani, Iran, Neilson, Hailey, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Kinder, Sheila, Kirtane, Ajay J., Radhakrishnan, Jai, Batres, Candido, Edwards, Suzanne, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Do, Danny, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Foster, Abby, Boyette, Alice, Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Peterson, Rose, Goldman, Jo Anne, Goldman, Jessie, Ledley, Gary, Katof, Nancy, Potluri, Srinivasa, Biedermann, Scott, Ward, Jacquelyn, White, Megan, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Smith, Alex, Aseltine, Laura, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Wade, Tyrone, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Semenec, Terence, Bloch, Michael J., Roongsritong, Chanwit, Nelson, Priscilla, Neumann, Bridget, Cohen, Debbie, Giri, Jay, Neubauer, Robin, Vo, Thu, Chugh, Atul R., Huang, Pei-Hsiu, Jose, Powell, Flack, John, Fishman, Robert, Jones, Michael, Adams, Todd, Bajzer, Christopher, Saxena, Manish, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Balawon, Armida, Zongo, Olivier, Levy, Terry, Bent, Clare, Beckett, David, Lakeman, Nicki, Kennard, Sarah, Sharp, Andrew, D’Souza, Richard J., Statton, Sarah, Wilkes, Lindsay, Anning, Christine, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Sevillano, Annaliza, Ocampo, Madelaine, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Sinclair, Janet, Pepper, Hayley, Davies, Justin, Chapman, Neil, Burak, Paula, Carvelli, Paula, Jadhav, Sachin, Quinn, Jane, Christian Rump, Lars, Stegbauer, Johannes, Schimmöller, Lars, Potthoff, Sebastian, Schmid, Claudia, Roeder, Sylvia, Weil, Joachim, Hafer, Lukas, Agdirlioglu, Tolga, Köllner, Tanja, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Kulenthiran, Saarraaken, Wachter, Angelika, Koch, Christina, Lurz, Philipp, Fengler, Karl, Rommel, Karl-Philipp, Trautmann, Kai, Petzold, Martin, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Heinritz, Ulrike, Fröhlich-Endres, Kerstin, Genth-Zotz, Sabine, Kämpfner, Denise, Grawe, Armin, Höhne, Johannes, Kaesberger, Bärbel, von zur Mühlen, Constantin, Wolf, Dennis, Welzel, Markus, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Maire, Florent, Gaudissard, Julie, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Livrozet, Marine, Lorthioir, Aurélien, Paquet, Valérie, Pathak, Atul, Honton, Benjamin, Cottin, Marianne, Petit, Frédéric, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Langevin, Fatou, Delsart, Pascal, Longere, Benjamin, Ledieu, Guillaume, Pontana, François, Sommeville, Coralie, Bertrand, Fabien, Daemen, Joost, Feyz, Lida, Zeijen, Victor, Ruiter, Arno, Huyskens, Elisabeth, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Dolmans, Helma, Kroon, A.A., van Zwam, W.H., Vranken, Jeannique, de Haan, Claudia, Persu, Alexandre, Renkin, Jean, Maes, Frédéric, Beauloye, Christophe, Lengelé, Jean-Philippe, Huyberechts, Dominique, Bouvier, Anne, Witkowski, Adam, Januszewicz, Andrzej, Kądziela, Jacek, Prejbisj, Aleksander, Hering, Dagmara, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Owczuk, Radoslaw, Ciecwierz, Dariusz, Jaguszewski, Milosz J., Wang, Yale, Jay, Desmond, Skeik, Nedaa, Schwartz, Robert, Rader, Florian, Dohad, Suhail, Victor, Ronald, Sanghvi, Kintur, Costello, Josh, Walsh, Courtney, Abraham, Josephine, Owan, Theophilus, Abraham, Anu, Fisher, Naomi D.L., Mauri, Laura, Sobieszczky, Piotr, Williams, Jonathan, Bloch, Michael J., Roongsritong, Chanwit, Todoran, Thomas, Basile, Jan, Powers, Eric, Hodskins, Emily, Fong, Pete, Laffer, Cheryl, Gainer, James, Robbins, Mark, Reilly, John, Cash, Michael, Goldman, Jessie, Aggarwal, Sandeep, Ledley, Gary, Hsi, David, Martin, Scott, Portnay, Edward, Calhoun, David, McElderry, Thomas, Maddox, William, Oparil, Suzanne, Huang, Pei-Hsiu, Jose, Powell, Khuddus, Matheen, Zentko, Suzanne, O’Meara, James, Barb, Ilie, Garasic, Joseph, Drachman, Doug, Zusman, Randy, Rosenfield, Kenneth, Devireddy, Chandan, Lea, Janice, Wells, Bryan, Stouffer, Rick, Hinderliter, Alan, Pauley, Eric, Potluri, Srinivasa, Biedermann, Scott, Bangalore, Sripal, Williams, Stephen, Zidar, David, Shishehbor, Mehdi, Effron, Barry, Costa, Marco, Kirtane, Ajay J., Radhakrishnan, Jai, Lobo, Melvin D., Mathur, Anthony, Jain, Ajay, Sayer, Jeremy, Ganesh Iyer, Sudha, Robinson, Nicholas, Ali Edroos, Sadat, Levy, Terry, Patel, Amit, Beckett, David, Bent, Clare, Davies, Justin, Chapman, Neil, Shun Shin, Matthew, Howard, James, Sharp, Andrew S.P., Joseph, Anil, D’Souza, Richard, Gerber, Robert, Faris, Mohamad, John Marshall, Andrew, Elorz, Cristina, Lurz, Philipp, Höllriegel, Robert, Fengler, Karl, Rommel, Karl-Philipp, Mahfoud, Felix, Böhm, Michael, Ewen, Sebastian, Lucic, Jelena, Schmieder, Roland E., Ott, Christian, Schmid, Axel, Uder, Michael, Rump, Christian, Stegbauer, Johannes, Kröpil, Patric, Azizi, Michel, Sapoval, Marc, Cornu, Erika, Fouassier, David, Gosse, Philippe, Cremer, Antoine, Trillaud, Hervé, Papadopoulos, Panteleimon, Pathak, Atul, Honton, Benjamin, Lantelme, Pierre, Berge, Constance, Courand, Pierre-Yves, Daemen, Joost, Feyz, Lida, Blankestijn, Peter, Voskuil, Michiel, Rittersma, Zwaantina, Kroon, A.A., van Zwam, W.H., Persu, Alexandre, and Renkin, Jean

Published
2024
Full Text
View/download PDF

5. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial

Author

Tan, Ngoc H, Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, GeurtsvanKessel, Corine H, de Vries, Rory D, and van der Kuy, P Hugo M

Published
2023
Full Text
View/download PDF

6. Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination

Author

Geers, Daryl, Sablerolles, Roos S.G., van Baarle, Debbie, Kootstra, Neeltje A., Rietdijk, Wim J.R., Schmitz, Katharina S., Gommers, Lennert, Bogers, Susanne, Nieuwkoop, Nella J., van Dijk, Laura L.A., van Haren, Eva, Lafeber, Melvin, Dalm, Virgil A.S.H., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Huckriede, Anke L.W., Sette, Alessandro, Grifoni, Alba, de Swart, Rik L., Koopmans, Marion P.G., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., and de Vries, Rory D.

Published
2023
Full Text
View/download PDF

9. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study

Author

Agnoletto, LA, Aleman, J, Andreassi, S, Andrews, LM, Ashfield, L, Bell, H, Bengaard, AKB, Berlinghini, SB, Bini, KB, Bisoffi, ZB, Blum, KB, Boemaars, E, Boni, GB, Bosch, TM, Bosma, BE, Boutkourt, F, Bufarini, C, Bulsink, A, Cabuk, RC, Callens, GC, Candela, MC, Canonici, MC, Capone, EC, Carmo, IC, Caruso, FC, Chessa, PC, Cohet, GC, Cornelissen-Wesseling, I, Crommentuijn, KML, de Stoppelaar, FM, de Wit, HAJM, Deben, DS, Derijks, LJJ, Di Carlo, MDC, Diepstraten, J, Dilek, B, Duchek-Mann, DMK, Ebbens, MM, Ellerbroek, LJ, Ezinga, M, Falcao, MF, Falcao, FF, Fantini, LF, Farinha, HF, Filius, PMG, Fitzhugh, NJ, Fleming, G, Forsthuber, TF, Gambarelli, GG, Gambera, MG, García Yubero, CGY, Getrouw, Z, Ghazarian, CN, Goodfellow, N, Gorgas, MQG, Grinta, RG, Guda, K, Haider, DH, Hanley, J, Heitzeneder, KH, Hemminga, WL, Hendriksen, LC, Hilarius, DL, Hogenhuis, FEF, Hoogendoorn-de Graaf, IC, Houlind, MBH, Huebler, MAH, Hurkens, KPGM, Janssen, PKC, Jong, E, Kappers, MHW, Keijzers, KFM, Kemogni, MK, Kemper, EM, Kranenburg, RA, Krens, LL, Le Grand, JL G, Liang, J, Lim, S, Lindner, NL, Loche, EL, Lubich, AL, Maat, B, Maesano, CM, Maiworm, AM, Maragna, M, Marchesini, FM, Martignoni, IM, Martini, G M, Masini, CM, Mc Menamin, R, Mendes, DM, Miarons, M, Moorlag, R, Müller, MR, Nagele, FN, Nemec, KN, Oka, GO, Otten-Helmers, AG, Pagliarino, SP, Pappalardo, FP, Patel, M, Peverini, PM, Pieraccini, FP, Platania, EMP, Pons-Kerjean, NPK, Portillo Horcajada, LPH, Rametta, GR, Rijo, JR, Roelofsen, EE, Roobol-Meuwese, E, Rossi, LR, Russel, SAH, Safipour, Z, Salaffi, FS, Saleh, L, Schimizzi, AMS, Schols, JMGA, Schwap, MS, Scott, MG, Slijfer, EAM, Slob, EMA, Soares, JS, Solano, MS, Sombogaard, F, Stemer, GS, Tardella, MT, ter Horst, PGJ, Tessari, RT, Tournoy, J, van den Berg, RB, Van der Linden, L, van der Linden, PD, van Dijk, SC, Van Etten, RW, van Haelst, IMM, van Heuckelum, M, van Kan, HJM, van Nieuwkoop, C, van Onzenoort, HAW, van Wijngaarden, P, Verdonk, JDJ, Verri, Fv, Verstijnen, JAMC, Veyrier, MV, Viegas, EV, Visser, LE, Vos, A, Vromen, MAM, Wierenga, PC, Wong, DR, Zenico, CZ, Zuppini, TZ, Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, and Faes, Miriam C

Published
2021
Full Text
View/download PDF

10. Original COVID-19 priming regimen impacts the immunogenicity of bivalent BA.1 and BA.5 boosters

Author

Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, de Vries, Rory D, Zaeck, Luca M, Tan, Ngoc H, Rietdijk, Wim J R, Geers, Daryl, Sablerolles, Roos S G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Rugebregt, Sharona, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, Haagmans, Bart L, van Baarle, Debbie, Koopmans, Marion P G, van der Kuy, P Hugo M, GeurtsvanKessel, Corine H, and de Vries, Rory D

Abstract

Waning antibody responses after COVID-19 vaccination combined with the emergence of the SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, bivalent mRNA-based booster vaccines encoding the ancestral spike protein in combination with that of Omicron BA.1 or BA.5 were introduced. Since then, different BA.2-descendent lineages have become dominant, such as XBB.1.5, JN.1, or EG.5.1. Here, we report post-hoc analyses of data from the SWITCH-ON study, assessing how different COVID-19 priming regimens affect the immunogenicity of bivalent booster vaccinations and breakthrough infections (NCT05471440). BA.1 and BA.5 bivalent vaccines boosted neutralizing antibodies and T-cells up to 3 months after boost; however, cross-neutralization of XBB.1.5 was poor. Interestingly, different combinations of prime-boost regimens induced divergent responses: participants primed with Ad26.COV2.S developed lower binding antibody levels after bivalent boost while neutralization and T-cell responses were similar to mRNA-based primed participants. In contrast, the breadth of neutralization was higher in mRNA-primed and bivalent BA.5 boosted participants. Combined, our data further support the current use of monovalent vaccines based on circulating strains when vaccinating risk groups, as recently recommended by the WHO. We emphasize the importance of the continuous assessment of immune responses targeting circulating variants to guide future COVID-19 vaccination policies.

Published
2024

11. Monitoring antihypertensive drug concentrations to determine nonadherence in hypertensive patients with or without a kidney transplant

Author

Peeters, Laura E.J., primary, Hesselink, Dennis A., additional, Lafeber, Melvin, additional, Severs, David, additional, van den Hoogen, Martijn W.F., additional, Sonneveld, Michelle A.H., additional, Ramakers, Christian R.B., additional, Bahmany, Soma, additional, van Gelder, Teun, additional, Koch, Birgit C.P., additional, and Versmissen, Jorie, additional

Published
2023
Full Text
View/download PDF

13. Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON):results from the direct boost group of an open-label, multicentre, randomised controlled trial

Author

Tan, Ngoc H., Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, Geurts van Kessel, Corine H., de Vries, Rory D, van der Kuy, P Hugo M, Tan, Ngoc H., Geers, Daryl, Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Bogers, Susanne, van Dijk, Laura L A, Gommers, Lennert, van Leeuwen, Leanne P M, Boerma, Annemarie, Nijhof, Sander H, van Dort, Karel A, Koopmans, Marion P G, Dalm, Virgil A S H, Lafeber, Melvin, Kootstra, Neeltje A, Huckriede, Anke L W, van Baarle, Debbie, Zaeck, Luca M, Geurts van Kessel, Corine H., de Vries, Rory D, and van der Kuy, P Hugo M

Abstract

Background: Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron spike (S) protein were developed as a countermeasure against antigenically distinct SARS-CoV-2 variants. We aimed to assess the (variant-specific) immunogenicity and reactogenicity of mRNA-based bivalent omicron (BA.1) vaccines in individuals who were primed with adenovirus-based or mRNA-based vaccines encoding the ancestral spike protein. Methods: We analysed results of the direct boost group of the SWITCH ON study, an open-label, multicentre, randomised controlled trial. Health-care workers from four academic hospitals in the Netherlands aged 18–65 years who had completed a primary COVID-19 vaccination regimen and received one booster of an mRNA-based vaccine, given no later than 3 months previously, were eligible. Participants were randomly assigned (1:1) using computer software in block sizes of 16 and 24 to receive an omicron BA.1 bivalent booster straight away (direct boost group) or a bivalent omicron BA.5 booster, postponed for 90 days (postponed boost group), stratified by priming regimen. The BNT162b2 OMI BA.1 boost was given to participants younger than 45 years, and the mRNA-1273.214 boost was given to participants 45 years or older, as per Dutch guidelines. The direct boost group, whose results are presented here, were divided into four subgroups for analysis: (1) Ad26.COV2.S (Johnson & Johnson) prime and BNT162b2 OMI BA.1 (BioNTech–Pfizer) boost (Ad/P), (2) mRNA-based prime and BNT162b2 OMI BA.1 boost (mRNA/P), (3) Ad26.COV2.S prime and mRNA-1273.214 (Moderna) boost (Ad/M), and (4) mRNA-based prime and mRNA-1273.214 boost (mRNA/M). The primary outcome was fold change in S protein S1 subunit-specific IgG antibodies before and 28 days after booster vaccination. The primary outcome and safety were assessed in all participants except those who withdrew, had a SARS-CoV-2 breakthrough infection, or had a missing blood sample at day 0 or day 28. This tria

Published
2023

14. Association between renal sympathetic denervation and arterial stiffness:the ASORAS study

Author

Zeijen, Victor J M, Feyz, Lida, Kardys, Isabella, Geleijnse, Marcel L, Van Mieghem, Nicolas M, Zijlstra, Felix, Lafeber, Melvin, Van Der Geest, Rob J, Hirsch, Alexander, Daemen, Joost, Zeijen, Victor J M, Feyz, Lida, Kardys, Isabella, Geleijnse, Marcel L, Van Mieghem, Nicolas M, Zijlstra, Felix, Lafeber, Melvin, Van Der Geest, Rob J, Hirsch, Alexander, and Daemen, Joost

Abstract

OBJECTIVES: Renal sympathetic denervation (RDN) reduces blood pressure (BP). However, one out of three patients does not exhibit a significant BP response to the therapy. This study investigates the association between noninvasive vascular stiffness indices and RDN-mediated BP reduction.METHODS: In this prospective, single-arm pilot study, patients with systolic office BP at least 140 mmHg, mean 24-h systolic ambulatory blood pressure (ABP) at least 130 mmHg and at least three prescribed antihypertensive drugs underwent radiofrequency RDN. The primary efficacy endpoint was temporal evolution of mean 24-h systolic ABP throughout 1-year post RDN (measured at baseline and 3-6-12 months). Effect modification was studied for baseline ultrasound carotid-femoral and magnetic resonance (MR) pulse wave velocity (PWV), MR aortic distensibility, cardiac MR left ventricular parameters and clinical variables. Statistical analyses were performed using linear mixed-effects models, and effect modification was assessed using interaction terms.RESULTS: Thirty patients (mean age 62.5 ± 10.7 years, 50% women) with mean 24-h ABP 146.7/80.8 ± 13.7/12.0 mmHg were enrolled. Following RDN, mean 24-h systolic ABP changed with -8.4 (95% CI: -14.5 to -2.3) mmHg/year (P = 0.007). Independent effect modifiers were CF-PWV [+2.7 (0.3 to 5.1) mmHg/year change in outcome for every m/s increase in CF-PWV; P = 0.03], daytime diastolic ABP [-0.4 (-0.8 to 0.0) mmHg/year per mmHg; P = 0.03], age [+0.6 (0.2 to 1.0) mmHg/year per year of age; P = 0.006], female sex [-14.0 (-23.1 to -5.0) mmHg/year as compared with men; P = 0.003] and BMI [+1.2 (0.1 to 2.2) mmHg/year per kg/m2; P = 0.04].CONCLUSION: Higher CF-PWV at baseline was associated with a smaller reduction in systolic ABP following RDN. These findings could contribute to improve identification of RDN responders.

Published
2023

15. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers

Author

Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., GeurtsvanKessel, Corine H., Sablerolles, Roos S.G., Rietdijk, Wim J.R., Goorhuis, Abraham, Postma, Douwe F., Visser, Leo G., Schmitz, Katharina S., Geers, Daryl, Bogers, Susanne, van Haren, Eva, Koopmans, Marion P.G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, van Baarle, Debbie, de Vries, Rory D., van der Kuy, P. Hugo M., and GeurtsvanKessel, Corine H.

Abstract

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2-specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed.

Published
2023

16. Wanneer gaan we patiënten een ‘polypil’ geven?

Author

Lafeber, Melvin, Peeters, Laura, Versmissen, Jori, Pharmacy, and Internal Medicine

Abstract

The 'polypill' stands for fixed-dosed combination pills with generic drugs that act on multiple cardiovascular risk factors. Data from randomized controlled trials show consistent beneficial effects of treatment with a polypill on both cardiovascular risk factors and relevant marjor cardiovascular endpoints. However, polypills are not readily available worldwide and only a limited number of polypills is marketed in Europe. Physicians have to embrace polypills in regular care to let the patient benefit from the advantages of the polypill. Licensing more polypills is an essential step to implement these pills in clinical care. Regulatory agencies need to reduce the dossier content requirements for registrations of new fixed-dosed combination pills so generic pharmaceutical companies can expand the number of marketed polypills.

Published
2023

17. Nocebo-effecten van statines

Author

Lafeber, Melvin, Evers, Andrea W M, Klok, Frederikus A, Pharmacy, Internal Medicine, and Health Economics (HE)

Abstract

Statins are effective drugs that can reduce the risk of new cardiovascular events. Although in randomized, placebo-controlled trials statins are associated with a low risk of mild muscle complaints such as myalgia, in daily practice up to 30% of patients report complaints attributed to statin use. Two recent studies have shown statin-associated muscle complaints are mainly related to the nocebo effect. The nocebo effect is a decrease in benefit and/or a new onset or worsening of adverse effects due to an expectation of harm associated with the treatment. Statins face reputational challenges due to a vast amount of negative attention on the internet. We need to address the nocebo effect by managing the perception of statins and provide patients with objective information about statin treatment, reduce the negative expectations, and placing discussion about the likelihood of adverse effects into the context of treatment benefit.

Published
2023

19. PS-C27-3: MEASURING ANTIHYPERTENSIVE DRUG CONCENTRATIONS TO DETERMINE NON-ADHERENCE IN HYPERTENSIVE PATIENTS WITH AND WITHOUT KIDNEY TRANSPLANTATION

Author

Peeters, Laura EJ, primary, Hesselink, Dennis A, additional, de Winter, Brenda CM, additional, Lafeber, Melvin, additional, Severs, David, additional, van den Hoogen, Martijn WF, additional, Sonneveld, Michelle AH, additional, Ramakers, Chris RB, additional, Bahmany, Soma, additional, van Gelder, Teun, additional, Koch, Birgit CP, additional, and Versmissen, Jorie, additional

Published
2023
Full Text
View/download PDF

20. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol

Author

Tan, Ngoc H., primary, Sablerolles, Roos S. G., additional, Rietdijk, Wim J. R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Bogers, Susanne, additional, Geers, Daryl, additional, Zaeck, Luca M., additional, Koopmans, Marion P. G., additional, Dalm, Virgil A. S. H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L. W., additional, van Baarle, Debbie, additional, Lafeber, Melvin, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, Paul-Hugo Marie, additional

Published
2022
Full Text
View/download PDF

22. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study

Author

Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, Kuy, Hugo, Internal Medicine, Pharmacy, and Cardiology

Subjects
medicine.medical_specialty, Angiotensin-Converting Enzyme Inhibitors, angiotensin‐converting enzyme inhibitor, 030226 pharmacology & pharmacy, SARS‐CoV‐2, law.invention, Angiotensin Receptor Antagonists, 03 medical and health sciences, 0302 clinical medicine, COVID‐19, law, Internal medicine, Clinical endpoint, medicine, Humans, Pharmacology (medical), 030212 general & internal medicine, Retrospective Studies, Pharmacology, biology, SARS-CoV-2, business.industry, Incidence (epidemiology), COVID-19, Angiotensin-converting enzyme, Original Articles, Emergency department, Odds ratio, mortality, Intensive care unit, Hospitals, Confidence interval, angiotensin II receptor blocker, Hypertension, biology.protein, Original Article, Observational study, business
Abstract

Since the outbreak of SARS-CoV-2, also known as COVID-19, conflicting theories have circulated on the influence of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) on incidence and clinical course of COVID-19, but data are scarce. The COvid MEdicaTion (COMET) study is an observational, multinational study that focused on the clinical course of COVID-19 (i.e. hospital mortality and intensive care unit [ICU] admission), and included COVID-19 patients who were registered at the emergency department or admitted to clinical wards of 63 participating hospitals. Pharmacists, clinical pharmacologists or treating physicians collected data on medication prescribed prior to admission. The association between the medication and composite clinical endpoint, including mortality and ICU admission, was analysed by multivariable logistic regression models to adjust for potential confounders. A total of 4870 patients were enrolled. ACEi were used by 847 (17.4%) patients and ARB by 761 (15.6%) patients. No significant association was seen with ACEi and the composite endpoint (adjusted odds ratio [OR] 0.94; 95% confidence interval [CI] 0.79 to 1.12), mortality (OR 1.03; 95%CI 0.84 to 1.27) or ICU admission (OR 0.96; 95%CI 0.78 to 1.19) after adjustment for covariates. Similarly, no association was observed between ARB and the composite endpoint (OR 1.09; 95%CI 0.90 to 1.30), mortality (OR 1.12; OR 0.90 to 1.39) or ICU admission (OR 1.21; 95%CI 0.98 to 1.49). In conclusion, we found no evidence of a harmful or beneficial effect of ACEi or ARB use prior to hospital admission on ICU admission or hospital mortality.

Published
2021

24. Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers:The SWITCH ON trial protocol

Author

Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, van der Kuy, Hugo, Tan, Wendy, Sablerolles, Roos, Rietdijk, Wim, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G., Bogers, Susanne, Geers, Daryl, Zaeck, Luca M., Koopmans, Marion, Dalm, V.A.S.H., Kootstra, Neeltje A., Huckriede, Anke L.W., van Baarle, Debbie, Lafeber, Melvin, Geurts van Kessel, Corine, de Vries, Rory, and van der Kuy, Hugo

Abstract

Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing protection against severe disease, thereby reducing hospital admissions and deaths. Several studies have reported reduction in vaccine effectiveness over time against the Omicron sub-lineages. However, the willingness to receive regular booster doses in the general population is declining. To determine the need for repeated booster vaccinations in healthy individuals and to aid policymakers in future public health interventions for COVID-19, we aim to gain insight into the immunogenicity of the additional bivalent booster vaccination in a representative sample of the healthy Dutch population. The SWITCH ON study was initiated to investigate three main topics: i) immunogenicity of bivalent vaccines after priming with adenovirus- or mRNA-based vaccines, ii) immunological recall responses and reactivity with relevant variants after booster vaccination, and iii) the necessity of booster vaccinations for the healthy population in the future. Clinical trial registration: https://clinicaltrials.gov/, identifier NCT05471440.

Published
2022

25. Adequacy of blood pressure control in high-risk hypertensive patients:The DEGREE study

Author

Zeijen, Victor J M, Lafeber, Melvin, Versmissen, Jorie, Kroon, Abraham A, Boersma, Eric, Daemen, Joost, Zeijen, Victor J M, Lafeber, Melvin, Versmissen, Jorie, Kroon, Abraham A, Boersma, Eric, and Daemen, Joost

Abstract

INTRODUCTION: Hypertension is a modifiable risk factor in patients at the highest risk for cardiovascular events. New invasive treatment options are becoming available that might be particularly appealing for high-risk patients. Therefore, the aim of this study was to determine the prevalence of high-risk patients on routine therapy that do not meet guideline recommended ambulatory blood pressure (ABP) targets.METHODS: This single-center, cross-sectional study was conducted at the Erasmus University Medical Center (Rotterdam, The Netherlands). Inclusion criteria were: (1) age 18-80 years, (2) drugs prescribed for hypertension or history of hypertension and (3) high cardiovascular risk as defined according to the European Society of Cardiology/European Society of Hypertension (ESC/ESH) guidelines. Patients underwent standardized office blood pressure (OBP) and same-day 24-h ABP measurements. Blood pressure (BP) control was defined according to the 2018 ESC/ESH and 2017 American College of Cardiology/American Heart Association (ACC/AHA) guidelines.RESULTS: A total of 100 patients were enrolled (median age 71 years, 35% female). Mean OBP was 142.2/81.9 ± 18.6/12.6 mmHg and mean 24-h ABP was 126.1/70.1 ± 14.3/9.2 mmHg. Patients were on 2.0 [25th-75th percentile: 1.0-3.3] Defined Daily Doses of antihypertensive drugs. ESC/ESH guideline 24-h ABP and OBP targets were not met in 41.8% (95%CI: 31.5-52.6%) and 52.7% (95%CI: 42.0-63.3%), respectively. ACC/AHA guideline 24-h ABP and OBP targets were not met in 59.3% (95%CI: 48.5-69.5%) and 79.1% (95%CI: 69.3-86.9%), respectively.CONCLUSIONS: BP remains uncontrolled in 40-60% of high-risk hypertensive patients despite routine use of guideline-recommended therapy. Our findings support the search towards novel invasive BP lowering treatment options.

Published
2022

26. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming

Author

Sablerolles, Roos S.G., primary, Rietdijk, Wim J.R., additional, Goorhuis, Abraham, additional, Postma, Douwe F., additional, Visser, Leo G., additional, Geers, Daryl, additional, Schmitz, Katharina S., additional, Garcia Garrido, Hannah M., additional, Koopmans, Marion P.G., additional, Dalm, Virgil A.S.H., additional, Kootstra, Neeltje A., additional, Huckriede, Anke L.W., additional, Lafeber, Melvin, additional, van Baarle, Debbie, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, and van der Kuy, P. Hugo M., additional

Published
2022
Full Text
View/download PDF

27. Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.

Author

Sablerolles, Roos S G, Rietdijk, Wim J R, Goorhuis, Abraham, Postma, Douwe F, Visser, Leo G, Schmitz, Katharina S, Geers, Daryl, Bogers, Susanne, Haren, Eva van, Koopmans, Marion P G, Dalm, Virgil A S H, Kootstra, Neeltje A, Huckriede, Anke L W, Akkerman, Renate, Beukema, Martin, Lafeber, Melvin, Baarle, Debbie van, Vries, Rory D de, Kuy, P Hugo M van der, and GeurtsvanKessel, Corine H

Subjects
COVID-19, IMMUNOGLOBULINS, COVID-19 vaccines, TIME, IMMUNE system, RESEARCH funding, DRUG allergy
Abstract

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We found that SARS-CoV-2–specific binding antibodies, neutralizing antibodies, and T cells are detectable 5 months after boosting, although waning of antibodies and limited cross-reactivity with Omicron BA.1 was observed. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

29. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol

Author

Sablerolles, Roos S. G., primary, Goorhuis, Abraham, additional, GeurtsvanKessel, Corine H., additional, de Vries, Rory D., additional, Huckriede, Anke L. W., additional, Koopmans, Marion P. G., additional, Lafeber, Melvin, additional, Postma, Douwe F., additional, van Baarle, Debbie, additional, Visser, Leo G., additional, Dalm, Virgil A. S. H., additional, Kootstra, Neeltje A., additional, Rietdijk, Wim J. R., additional, and van der Kuy, P. Hugo M., additional

Published
2021
Full Text
View/download PDF

30. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET):an international, multicentre, retrospective, observational cohort study

Author

Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, Faes, Miriam C, Sablerolles, Roos S G, Lafeber, Melvin, van Kempen, Janneke A L, van de Loo, Bob P A, Boersma, Eric, Rietdijk, Wim J R, Polinder-Bos, Harmke A, Mooijaart, Simon P, van der Kuy, Hugo, Versmissen, Jorie, and Faes, Miriam C

Abstract

Background: During the COVID-19 pandemic, the scarcity of resources has necessitated triage of critical care for patients with the disease. In patients aged 65 years and older, triage decisions are regularly based on degree of frailty measured by the Clinical Frailty Scale (CFS). However, the CFS could also be useful in patients younger than 65 years. We aimed to examine the association between CFS score and hospital mortality and between CFS score and admission to intensive care in adult patients of all ages with COVID-19 across Europe. Methods: This analysis was part of the COVID Medication (COMET) study, an international, multicentre, retrospective observational cohort study in 63 hospitals in 11 countries in Europe. Eligible patients were aged 18 years and older, had been admitted to hospital, and either tested positive by PCR for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or were judged to have a high clinical likelihood of having SARS-CoV-2 infection by the local COVID-19 expert team. CFS was used to assess level of frailty: fit (CFS 1–3), mildly frail (CFS 4–5), or frail (CFS 6–9). The primary outcome was hospital mortality. The secondary outcome was admission to intensive care. Data were analysed using a multivariable binary logistic regression model adjusted for covariates (age, sex, number of drugs prescribed, and type of drug class as a proxy for comorbidities). Findings: Between March 30 and July 15, 2020, 2434 patients (median age 68 years [IQR 55–77]; 1480 [61%] men, 954 [30%] women) had CFS scores available and were included in the analyses. In the total sample and in patients aged 65 years and older, frail patients and mildly frail patients had a significantly higher risk of hospital mortality than fit patients (total sample: CFS 6–9 vs CFS 1–3 odds ratio [OR] 2·71 [95% CI 2·04–3·60], p<0·0001 and CFS 4–5 vs CFS 1–3 OR 1·54 [1·16–2·06], p=0·0030; age

Published
2021

31. Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens:The SWITCH Trial Protocol

Author

Sablerolles, Roos S.G., Goorhuis, Abraham, GeurtsvanKessel, Corine H., de Vries, Rory D., Huckriede, Anke L.W., Koopmans, Marion P.G., Lafeber, Melvin, Postma, Douwe F., van Baarle, Debbie, Visser, Leo G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Rietdijk, Wim J.R., van der Kuy, P. Hugo M., Sablerolles, Roos S.G., Goorhuis, Abraham, GeurtsvanKessel, Corine H., de Vries, Rory D., Huckriede, Anke L.W., Koopmans, Marion P.G., Lafeber, Melvin, Postma, Douwe F., van Baarle, Debbie, Visser, Leo G., Dalm, Virgil A.S.H., Kootstra, Neeltje A., Rietdijk, Wim J.R., and van der Kuy, P. Hugo M.

Published
2021

32. Association between Clinical Frailty Scale score and hospital mortality in adult patients with COVID-19 (COMET): an international, multicentre, retrospective, observational cohort study

Author

Sablerolles, Roos S G, primary, Lafeber, Melvin, additional, van Kempen, Janneke A L, additional, van de Loo, Bob P A, additional, Boersma, Eric, additional, Rietdijk, Wim J R, additional, Polinder-Bos, Harmke A, additional, Mooijaart, Simon P, additional, van der Kuy, Hugo, additional, Versmissen, Jorie, additional, Faes, Miriam C, additional, Agnoletto, LA, additional, Aleman, J, additional, Andreassi, S, additional, Andrews, LM, additional, Ashfield, L, additional, Bell, H, additional, Bengaard, AKB, additional, Berlinghini, SB, additional, Bini, KB, additional, Bisoffi, ZB, additional, Blum, KB, additional, Boemaars, E, additional, Boni, GB, additional, Bosch, TM, additional, Bosma, BE, additional, Boutkourt, F, additional, Bufarini, C, additional, Bulsink, A, additional, Cabuk, RC, additional, Callens, GC, additional, Candela, MC, additional, Canonici, MC, additional, Capone, EC, additional, Carmo, IC, additional, Caruso, FC, additional, Chessa, PC, additional, Cohet, GC, additional, Cornelissen-Wesseling, I, additional, Crommentuijn, KML, additional, de Stoppelaar, FM, additional, de Wit, HAJM, additional, Deben, DS, additional, Derijks, LJJ, additional, Di Carlo, MDC, additional, Diepstraten, J, additional, Dilek, B, additional, Duchek-Mann, DMK, additional, Ebbens, MM, additional, Ellerbroek, LJ, additional, Ezinga, M, additional, Falcao, MF, additional, Falcao, FF, additional, Fantini, LF, additional, Farinha, HF, additional, Filius, PMG, additional, Fitzhugh, NJ, additional, Fleming, G, additional, Forsthuber, TF, additional, Gambarelli, GG, additional, Gambera, MG, additional, García Yubero, CGY, additional, Getrouw, Z, additional, Ghazarian, CN, additional, Goodfellow, N, additional, Gorgas, MQG, additional, Grinta, RG, additional, Guda, K, additional, Haider, DH, additional, Hanley, J, additional, Heitzeneder, KH, additional, Hemminga, WL, additional, Hendriksen, LC, additional, Hilarius, DL, additional, Hogenhuis, FEF, additional, Hoogendoorn-de Graaf, IC, additional, Houlind, MBH, additional, Huebler, MAH, additional, Hurkens, KPGM, additional, Janssen, PKC, additional, Jong, E, additional, Kappers, MHW, additional, Keijzers, KFM, additional, Kemogni, MK, additional, Kemper, EM, additional, Kranenburg, RA, additional, Krens, LL, additional, Le Grand, JL G, additional, Liang, J, additional, Lim, S, additional, Lindner, NL, additional, Loche, EL, additional, Lubich, AL, additional, Maat, B, additional, Maesano, CM, additional, Maiworm, AM, additional, Maragna, M, additional, Marchesini, FM, additional, Martignoni, IM, additional, Martini, G M, additional, Masini, CM, additional, Mc Menamin, R, additional, Mendes, DM, additional, Miarons, M, additional, Moorlag, R, additional, Müller, MR, additional, Nagele, FN, additional, Nemec, KN, additional, Oka, GO, additional, Otten-Helmers, AG, additional, Pagliarino, SP, additional, Pappalardo, FP, additional, Patel, M, additional, Peverini, PM, additional, Pieraccini, FP, additional, Platania, EMP, additional, Pons-Kerjean, NPK, additional, Portillo Horcajada, LPH, additional, Rametta, GR, additional, Rijo, JR, additional, Roelofsen, EE, additional, Roobol-Meuwese, E, additional, Rossi, LR, additional, Russel, SAH, additional, Safipour, Z, additional, Salaffi, FS, additional, Saleh, L, additional, Schimizzi, AMS, additional, Schols, JMGA, additional, Schwap, MS, additional, Scott, MG, additional, Slijfer, EAM, additional, Slob, EMA, additional, Soares, JS, additional, Solano, MS, additional, Sombogaard, F, additional, Stemer, GS, additional, Tardella, MT, additional, ter Horst, PGJ, additional, Tessari, RT, additional, Tournoy, J, additional, van den Berg, RB, additional, Van der Linden, L, additional, van der Linden, PD, additional, van Dijk, SC, additional, Van Etten, RW, additional, van Haelst, IMM, additional, van Heuckelum, M, additional, van Kan, HJM, additional, van Nieuwkoop, C, additional, van Onzenoort, HAW, additional, van Wijngaarden, P, additional, Verdonk, JDJ, additional, Verri, Fv, additional, Verstijnen, JAMC, additional, Veyrier, MV, additional, Viegas, EV, additional, Visser, LE, additional, Vos, A, additional, Vromen, MAM, additional, Wierenga, PC, additional, Wong, DR, additional, Zenico, CZ, additional, and Zuppini, TZ, additional

Published
2021
Full Text
View/download PDF

37. COvid MEdicaTion (COMET) study:protocol for a cohort study

Author

Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, van der Kuy, Hugo M., Sablerolles, Roos S. G., Hogenhuis, Freija E. F., Lafeber, Melvin, van de Loo, Bob P. A., Borgsteede, Sander D., Boersma, Eric, Versmissen, Jorie, and van der Kuy, Hugo M.

Abstract

Various theories about drugs such as ACE inhibitors or angiotensin II receptor blockers (ARBs) in relation to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and clinical outcomes of COVID-19 are circulating in both mainstream media and medical literature. These are based on the fact that ACE2 facilitates SARS-CoV-2 cell invasion via binding of a viral spike protein to ACE2. However, the effect of ACE inhibitors, ARBs and other drugs on ACE2 is unclear and all theories are based on conflicting evidence mainly from animal studies. Therefore, clinical evidence is urgently needed. The aim of this study is to investigate the relationship between use of these drugs on clinical outcome of patients with COVID-19. Patients will be included from several hospitals in Europe. Data will be collected in a user-friendly database (Digitalis) on an external server. Analyses will be adjusted for sex, age and presence of cardiovascular disease, hypertension and diabetes. These results will enable more rational choices for randomised controlled trials for preventive and therapeutic strategies in COVID-19.

Published
2020

38. PCSK9-remmers bij familiaire hypercholesterolemie.

Author

Lafeber, Melvin and Rongen, Gerard A.

Abstract

Copyright of Geneesmiddelenbulletin is the property of Stichting Geneesmiddelenbulletin and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2021

40. Combined use of polypill components in patients with type 2 diabetes mellitus

Author

Janssen, Vivi E., Visseren, Frank L., de Boer, Anthonius, Grobbee, Diederick E., Westerink, Jan, van der Graaf, Yolanda, Lafeber, Melvin, and SMART Study Group

Subjects
Epidemiology, Diabetic polypills, Fixed-dose combination drugs, Cardiovascular disease, Cardiology and Cardiovascular Medicine
Abstract

Objectives: A polypill containing aspirin, a statin and blood pressure (BP)-lowering agents has been proposed for the prevention of cardiovascular disease. To increase adherence and reduce the gaps between indicated and used therapy, a polypill might be of interest for patients with type 2 diabetes (T2DM). Our aim was to assess the prevalence of the combined use of polypill components in patients with T2DM over time. Methods: The combined use of polypill components was assessed between 1996 and 2015 in patients with T2DM in the prospective SMART cohort (n = 1828). The results were dichotomized into patients without (n = 568) and with (n = 1260) vascular disease. The patient characteristics associated with the use of polypill components were evaluated. Results: In total, 19% of patients with T2DM without vascular disease received a statin and ≥2 BP-lowering agents (‘cardiovascular polypill’) and 13% received additional oral glucose-lowering therapy (‘diabetic polypill’). Of the patients with T2DM with vascular disease, 42% received the combination of an antiplatelet agent, a statin and ≥2 BP-lowering agents (‘cardiovascular polypill’) and 30% received additional glucose-lowering therapy (‘diabetic polypill’). The prevalence of the use of the cardiovascular and diabetic polypill combination has substantially increased between 1996 and 2015 to 36 and 32% in patients without vascular disease and to 67 and 57% in patients with vascular disease. Conclusions: Patients with T2DM frequently use polypill components, often together with oral glucose-lowering agents, and this rate of use has increased steadily between 1996 and 2015. Introducing a cardiovascular or diabetic polypill for patients with T2DM seems to be highly relevant.

Published
2018

41. De polypil bij hart- en vaatziekte : Waarom gebruiken we deze combinatiepillen zo weinig?

Author

Bots, Michiel L. and Lafeber, Melvin

Subjects
Medicine(all)
Abstract

Cardiovascular polypills or fixed-dose combination (FDC) therapy have been advocated to improve treatment and prevention of cardiovascular disease since 2003. Yet, it is still used infrequently in current practice. This is in contrast to the widespread use of fixed-dose drug combinations for HIV, tuberculosis, and malaria worldwide. Over the past 15 years, evidence from studies in patients with elevated cardiovascular risk or manifest cardiovascular disease has become available, showing that FDC therapy is a strategy which improves adherence, lowers risk factor levels better than usual care, improves adherence to treatment goals, considerably lowers daily intake of pills, and simplifies drug regimens. Furthermore, patients uniformly indicate that this type of therapy is preferred over prescription of individual pills. Also, FDC therapy is reimbursed. Yet, in the Netherlands, only a small percentage of patients is prescribed a fixed dose combination pill. This raises the question what the underlying barriers are to adoption in clinical practice: is it availability, willingness, awareness, or a combination of factors?

Published
2018

42. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk

Author

Lafeber, Melvin, Spiering, Wilko, Visseren, Frank Lj, Grobbee, Diederick E, Bots, Michiel L, Stanton, Alice, Patel, Anushka, Prabhakaran, Dorairaj, Webster, Ruth, Thom, Simon, Rodgers, Anthony, and UMPIRE investigators

Subjects
prevention, cardiovascular disease, fixed-dosed combination pill, statin, Journal Article, Antiplatelet, blood pressure-lowering agents, polypill
Abstract

Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the widespread lack of access and adherence to proven medicines. Initiation of polypill-based care typically entails switching from current separately taken medications. Given the heterogeneity in usual care, there is interest in the impact of polypill treatment across different patterns of prior medication regimen. Methods A total of 2004 participants with established cardiovascular disease or estimated 5-year cardiovascular risk of over 15% were randomised to polypill-based treatment (aspirin 75 mg, simvastatin 40 mg, lisinopril 10 mg and either atenolol 50 mg or hydrochlorothiazide 12.5 mg) or usual care. Baseline medications were classified by potency relative to polypill components. Estimated cardiovascular risk reduction was calculated by combining risk factor changes with results seen in meta-analyses of previous randomised trials. Results For cholesterol reduction conferred by polypills, there was a dose response across baseline statin groups, with mean low-density lipoprotein (LDL)-cholesterol differences of 0.37, 0.22, 0.14 and 0.07 mmol/L among patients taking no statin, less potent, equipotent and more potent statin at baseline, respectively. Similarly there were differences in mean systolic BP of 5.4, 6.2, 3.3 and 1.8 mmHg among patients taking 0, 1, 2 or 3 BP-lowering agents. Among patients taking more potent statins at baseline, there was no significant difference in LDL-cholesterol but there were benefits for BP and aspirin adherence. Similar results were seen among patients taking 3 BP-lowering agents at baseline. Switching to a polypill-based strategy resulted in estimated cardiovascular relative risk reductions across a wide range of usual care patterns of antiplatelet, statin and BP-lowering therapy prescribing. Conclusion Adherence benefits from switching to a polypill resulted in risk factor changes that were at least as good as usual care across a wide variety of treatment patterns, including equally potent or more potent regimens. The benefits of switching to polypill-based care were greatest among those stepped up from partial treatment or less potent treatment.

Published
2017

46. Combined use of polypill components in patients with type 2 diabetes mellitus

Author

Interne Geneeskunde Vasculaire, Circulatory Health, Cardiovasculaire Epi Team 9, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Cardiovasculaire Epi Team 5, Unit Opleiding Aios, Janssen, Vivi E., Visseren, Frank L., de Boer, Anthonius, Grobbee, Diederick E., Westerink, Jan, van der Graaf, Yolanda, Lafeber, Melvin, SMART Study Group, Interne Geneeskunde Vasculaire, Circulatory Health, Cardiovasculaire Epi Team 9, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Cardiovasculaire Epi Team 5, Unit Opleiding Aios, Janssen, Vivi E., Visseren, Frank L., de Boer, Anthonius, Grobbee, Diederick E., Westerink, Jan, van der Graaf, Yolanda, Lafeber, Melvin, and SMART Study Group

Published
2018

47. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk

Author

Unit Opleiding Aios, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Interne Geneeskunde Vasculaire, Cardiovasculaire Epi Team 9, Cardiovasculaire Epi Team 5, Lafeber, Melvin, Spiering, Wilko, Visseren, Frank Lj, Grobbee, Diederick E, Bots, Michiel L, Stanton, Alice, Patel, Anushka, Prabhakaran, Dorairaj, Webster, Ruth, Thom, Simon, Rodgers, Anthony, UMPIRE investigators, Unit Opleiding Aios, Circulatory Health, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, MS Interne Geneeskunde, Interne Geneeskunde Vasculaire, Cardiovasculaire Epi Team 9, Cardiovasculaire Epi Team 5, Lafeber, Melvin, Spiering, Wilko, Visseren, Frank Lj, Grobbee, Diederick E, Bots, Michiel L, Stanton, Alice, Patel, Anushka, Prabhakaran, Dorairaj, Webster, Ruth, Thom, Simon, Rodgers, Anthony, and UMPIRE investigators

Published
2017

49. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease

Author

Cardiovasculaire Epi Team 10, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Unit Opleiding Aios, Interne Geneeskunde Vasculaire, Circulatory Health, Cardiovasculaire Epi Team 5, Cardiovasculaire Epi Team 9, MS Interne Geneeskunde, Lafeber, Melvin, Webster, Ruth, Visseren, Frank L J, Bots, Michiel L., Grobbee, Diederick E., Spiering, W., Rodgers, Anthony, Cardiovasculaire Epi Team 10, JC onderzoeksprogramma Cardiovasculaire Epidemiologie, Unit Opleiding Aios, Interne Geneeskunde Vasculaire, Circulatory Health, Cardiovasculaire Epi Team 5, Cardiovasculaire Epi Team 9, MS Interne Geneeskunde, Lafeber, Melvin, Webster, Ruth, Visseren, Frank L J, Bots, Michiel L., Grobbee, Diederick E., Spiering, W., and Rodgers, Anthony

Published
2016

50. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk: The influence of baseline medication on LDL-cholesterol, blood pressure and calculated risk reduction when switching to a cardiovascular polypill

Author

Lafeber, Melvin, Spiering, Wilko, Visseren, Frank LJ, Grobbee, Diederick E, Bots, Michiel L, Stanton, Alice, Patel, Anushka, Prabhakaran, Dorairaj, Webster, Ruth, Thom, Simon, and Rodgers, Anthony

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results